Esperion Therapeutis.Inc. diskutieren
Esperion Therapeutis.Inc.
WKN: A1W1SJ / Symbol: ESPR / Name: Esperion / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
2,33 €
-9,27 %
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $9.00 price target on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics (ESPR) had its price target raised by Needham & Company LLC from $4.00 to $5.00. They now have a "buy" rating on the stock.
Ratings data for ESPR provided by MarketBeat
Esperion Therapeutics (ESPR) had its "buy" rating reaffirmed by HC Wainwright.
Ratings data for ESPR provided by MarketBeat
Neueste Beiträge
UBS_Group_AG in Casella Waste Sys A diskutieren